Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma

Sarcomas are rare but highly aggressive mesenchymal tumors with a median survival of 10–18 months for metastatic disease. Mutation and/or overexpression of many receptor tyrosine kinases (RTKs) including c-Met, PDGFR, c-Kit and IGF1-R drive defective signaling pathways in sarcomas. MGCD516 (Sitravat...

Descripción completa

Detalles Bibliográficos
Autores principales: Patwardhan, Parag P., Ivy, Kathryn S., Musi, Elgilda, de Stanchina, Elisa, Schwartz, Gary K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826192/
https://www.ncbi.nlm.nih.gov/pubmed/26675259
http://dx.doi.org/10.18632/oncotarget.6547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826192/
https://www.ncbi.nlm.nih.gov/pubmed/26675259
http://dx.doi.org/10.18632/oncotarget.6547

Ejemplares similares